ALXO Stock — Alx Oncology Holdings

Alx Oncology Holdings (ALXO)

Updated October 16, 2026.

ALXO is a Stock. Total return is -96.5% over the past 6.2 years, 254.8 points behind SPY at 158.3%.

ALX Oncology Holdings is a clinical-stage immuno-oncology company developing cancer therapies, with its lead candidate Evorpacept, a CD47-blocking therapeutic being studied in combination with various anti-cancer agents across multiple tumor types including gastric cancer, breast cancer, and multiple myeloma through collaborations with major pharmaceutical partners and academic institutions. The company does not currently distribute dividends. This security appeals to investors with high risk tolerance seeking exposure to early-stage biopharmaceutical development.

ALXO performance versus SPY

Price and return data through 2026-10-16.

Total return is -96.5% over the past 6.2 years, 254.8 points behind SPY at 158.3%. Over the past year its total return — price change plus distributions reinvested — is -35.8%. Its deepest 1-year drawdown was 65.6%.

ALXO key facts

Asset type

Stock

Asset class

Equity

Inception date

07/17/2020

Distribution frequency

None

Last close

$1.06 (as of 2026-10-16)

Market cap

$146,573,617

Average volume

2428377.0

Beta

0.476

Payout ratio

0.0%

EPS

$-1.13

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ALXO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 65.6%.

Who may consider ALXO — and who may not

It is a weaker fit for investors who need monthly cash flow (ALXO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ALXO

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions